Alzamend Neuro (NASDAQ:ALZN) is a clinical-stage biotechnology company focused on the development of novel therapeutics for neurodegenerative and neuropsychiatric disorders. The company leverages a proprietary platform of peptide-based compounds designed to enhance neurotrophic support, stabilize microtubule dynamics, and improve mitochondrial function in the central nervous system. Alzamend’s scientific approach is centered on addressing the underlying biology of diseases such as Alzheimer’s, traumatic brain injury (TBI), and cognitive impairment associated with stroke, with the goal of delivering disease-modifying treatments where few options currently exist.
The company’s lead candidate, ALZ-101, is a small peptide agent targeting early-stage Alzheimer’s disease by promoting neuronal health and synaptic resilience. In parallel, Alzamend is advancing a second program aimed at accelerating recovery after ischemic stroke, using similar mechanisms of action to reduce neuronal damage and support functional restoration. Preclinical studies have demonstrated favorable safety and pharmacokinetic profiles across these assets, and the company has initiated phase 1 trials to evaluate tolerability and biological activity in human subjects.
Founded in 2017 and headquartered in San Diego, California, Alzamend Neuro has built a multidisciplinary team encompassing experts in neurology, pharmacology, and translational medicine. The company collaborates with leading academic institutions and research centers in North America, Europe, and Australia to accelerate its development programs and access advanced imaging and biomarker platforms. These partnerships aim to optimize clinical trial design and improve the likelihood of meaningful outcomes in patient populations.
Alzamend Neuro is led by Chief Executive Officer Ann Liebert, whose background spans senior roles in both biotechnology startups and established pharmaceutical companies, and Chief Scientific Officer Dr. Ivan Selko, an experienced neuroscientist with a track record in peptide therapeutics. Together, the leadership team is committed to advancing innovative treatments that address critical unmet needs in neurology and enhancing the quality of life for patients worldwide.
